Inovio Coronavirus Vaccine Candidate Trial Halted Due to FDA Inquiry

Inovio Pharmaceuticals (NASDAQ: INO) stock was really taking it on the chin Monday, following a very discouraging revelation from the company. The biotech announced that morning that the clinical trials for its INO-4800 COVID-19 vaccine candidate have been halted. This was because the Food and Drug Administration (FDA) served notice that it has additional questions about the phase 2/3 trial of INO-4800, in particular, the company's proprietary CELLECTRA 2000 injection device that will be used in the testing.